Squarepoint’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-62,618
Closed -$936K 4019
2022
Q4
$936K Buy
+62,618
New +$867K ﹤0.01% 1869
2021
Q2
Sell
-23,803
Closed -$174K 4014
2021
Q1
$174K Sell
23,803
-86,376
-78% -$745K ﹤0.01% 2752
2020
Q4
$636K Buy
110,179
+33,447
+44% +$191K ﹤0.01% 1628
2020
Q3
$456K Sell
76,732
-40,978
-35% -$203K 0.01% 1505
2020
Q2
$606K Buy
+117,710
New +$743K 0.01% 1201
2019
Q4
Sell
-1,596
Closed -$13K 2962
2019
Q3
$13K Buy
1,596
+255
+19% +$1.9K ﹤0.01% 2279
2019
Q2
$9K Buy
+1,341
New +$11.5K ﹤0.01% 2321
2017
Q4
Sell
-10,636
Closed -$388K 2449
2017
Q3
$388K Buy
+10,636
New +$329K 0.01% 1067

Squarepoint's AVEO Position: Q1 2023 in Review

Squarepoint sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q1 2023, closing a stake of 62,618 shares — an estimated $936K sold.

Squarepoint first reported a position in AVEO in Q3 2017 and held it in 8 quarters. The position peaked at $936K in Q4 2022. 0 funds tracked by Wall St. Rank hold AVEO as of Q1 2023.

  • Squarepoint reported no remaining AVEO Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
  • Squarepoint sold 62,618 AVEO Pharmaceuticals, Inc. shares in Q1 2023, an estimated $936K.
  • Squarepoint first reported a position in AVEO Pharmaceuticals, Inc. in Q3 2017 and held it in 8 quarters.
  • Squarepoint's AVEO Pharmaceuticals, Inc. position peaked at $936K in Q4 2022.
  • 0 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q1 2023.

Based on Squarepoint's 13F filing for Q1 2023, filed 15 May 2023.